ArticleNorthern clinics of Istanbul2025
The effects of chronic kidney disease stages on dyslipidemia, cardiovascular disease prevalence and mortality.
Article in Northern clinics of Istanbul, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Lipid Disorders in Patients with Renal Failure: Role in Cardiovascular Events and Progression of Chronic Kidney Disease.Life (Basel, Switzerland) · 2026Review
- Stress Pathways in Chronic Kidney Disease: Linking Cortisol, Oxidative Stress, and Inflammation.Antioxidants (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveCardiovascular disease (CVD) is the most common cause of death in chronic kidney disease (CKD) patients. The prevalence of CVD is significantly increased in CKD patients, and the frequency of CVD increases as the CKD stage worsens. Although atherosclerosis is more common in CKD patients, the lipid profile may change as the CKD stage changes. Many mechanisms cause this. Also, mortality is more common in patients with advanced CKD. In this study, we aim to emphasize the incidence of cardiovascular diseases and dyslipidemia in patients with CKD at different stages and the effect of these variable conditions on patient mortality.
methodsPatients who applied to the internal medicine outpatient clinic and were diagnosed with chronic kidney disease were examined. Mortality and complications were followed up for one year. A total of 1323 patients with a diagnosis of CKD between stages 3a-5 were included in the study. The relationships between kidney functions and lipid profiles, biochemical values, and prognosis of the patients were evaluated.
resultsNon-survivors had lower glomerular filtration rate (GFR) and higher C-reactive protein (CRP) levels. High-density lipoprotein (HDL), low-density lipoprotein (LDL), and albumin values decreased, and CRP increased as the disease stage progressed. More survivors had CKD and hyperlipidemia than non-survivors. It was observed that the stage remained the same in patients with hyperlipidemia at a higher rate. In contrast, the stage worsened or remained at stage 5 more in patients with cardiovascular disease or diabetes mellitus. Declining CKD stage and increasing CRP were influential risk factors that affect mortality.
conclusionIt is essential to closely monitor the changes in laboratory parameters at baseline and follow-up in CKD patients to predict or prevent comorbidities, mortality, and deterioration in patients' renal functions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.